결합 백신 시장 : 제품 종류별, 적응증별, 병원체 종류별, 환자 종류별, 지역별

Conjugate Vaccine Market is estimated to be valued at USD 25,966 Mn in 2026 and is expected to reach USD 49,220 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.6% from 2026 to 2033.

Conjugate vaccine is a combination of a weak antigen with a strong antigen so as to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, on January 24, 2022 according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. Whereas in 2021, US FDA (Food and Drug Administration) licensed PCV15 and PCV20 for use in adults 18 years or older. Clinical trial data showed that PCV15 and PCV20 caused the body's immune system to create antibodies, which helped fight the pneumococcal bacteria, similar to PCV13.

Market Dynamics

Increasing prevalence of pneumonia cases are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in August 2021, National Center for Biotechnology Information, published a report on Community-Acquired Pneumonia, which reported that the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the U.S., the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases, whereas the mortality rate is as high as 23% for patients admitted to the intensive care unit.

Increasing initiatives taken by the governments of countries to launch new vaccines are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in October 2021, Union Health Minister (India), Dr. Mansukh Mandaviya, launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) as a part of Azadi ka Amrit Mahotsav. Whereas, on the other hand communication and awareness packages on PVC were also made available in India.

Key features of the study

• This report provides an in-depth analysis of the global conjugate vaccine market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2030), considering 2021, as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
• It profiles key players in the global conjugate vaccine market based on following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include, Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, Bio-Med, Bavarian Nordic, CSL Limited, Novartis AG, Vaxcyte, GSBPL, Taj Pharmaceuticals Limited, and Bavarian Nordic
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global conjugate vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global conjugate vaccine market

Market Segmentation

• Product Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
• Disease Indication Insights (Revenue, USD Mn, 2026 - 2033)
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
• Pathogen Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Bacterial
  • Viral
• Patients Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Pediatric
  • Adults
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Sanofi S.A
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc.
  • Bharat Biotech
  • Serum institute of India Pvt. Ltd.
  • Biological E. Limited
  • Bio-Med
  • Bavarian Nordic
  • CSL Limited
  • Novartis AG
  • Vaxcyte
  • GSBPL
  • Taj Pharmaceuticals Limited
  • Bavarian Nordic

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
• Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Pathogen Type
  • Market Snapshot, By Patient Types
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Pipeline Analysis
• Investments and Government Initiatives
• GAVI and PATH Program Details
• Merger and Acquisition
• Regulatory Scenario
• PORTER'S Five Forces
• PEST Analysis

4. Global Conjugate Vaccine Market, By Product Type, 2026-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Monovalent Conjugate Vaccine
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Multivalent Conjugate Vaccine
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

5. Global Conjugate Vaccine Market, By Disease Indication, 2026-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Pneumococcal
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Influenza
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Meningococcal
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Typhoid
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

6. Global Conjugate Vaccine Market, By Pathogen Type, 2026-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Bacterial
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Viral
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

7. Global Conjugate Vaccine Market, By Patient Type,2026-2033, (USD Mn)

• Overview
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Paediatric
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Adult
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

8. Global Conjugate Vaccine Market, By Region, 2026-2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
• North America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026-2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Heat Map Analysis
• Company Profile
  • Sanofi S.A
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Pfizer, Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Merck & Co., Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • GlaxoSmithKline plc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Bharat Biotech
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Serum institute of India Pvt. Ltd
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Biological E. Limited.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Bio-Med
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Biological E Limited
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • CSL Limited
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Novartis AG
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Vaxcyte
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • GSBPL
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Taj Pharmaceuticals Limited.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Bavarian Nordic
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
• Analyst Views

10. Section

• References
• Research Methodology
• About Us